Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1. (Currently amended) A method of reducing glomerulosclerosis of a subject, said method comprising delivering a human cell comprising a nucleic acid encoding IL-10 to the kidney of ~~the~~ a human subject having glomerulosclerosis, wherein said cells express ~~in need thereof a therapeutically effective amount of a gene encoding~~ IL-10 to reduce glomerulosclerosis in said subject.

2-3. (Canceled)

4. (Currently amended) The method according to claim 1, wherein the ~~gene~~ nucleic acid is inserted into a vector.

5. (Previously presented) The method according to claim 4, wherein the vector is a virus.

6. (Previously presented) The method according to claim 5, wherein the virus is an adenovirus or an adenovirus-associated virus or retrovirus.

7. (Previously presented) The method according to claim 4, wherein the vector is a plasmid.

8. (Currently amended) The method according to claim 1, wherein the ~~gene~~ nucleic acid is transfected or infected into [[a]] said population of human cells *in vitro*, wherein the transfected or infected population of said cells is ~~administered~~ delivered to the subject.

9-17. (Canceled)

18. (Currently amended) A method of reducing progression of proteinuria in a subject, said method ~~suffering from a renal disorder~~ comprising delivering a human cell comprising a nucleic acid encoding IL-10 to the kidney of ~~the~~ a human subject having proteinuria, wherein said cells express ~~in need thereof a therapeutically effective amount of a gene encoding~~ IL-10 to reduce proteinuria in said subject.

19-20. (Canceled)

21. (Currently amended) The method according to claim 18, wherein the ~~gene~~ nucleic acid is inserted into a vector.

22. (Previously presented) The method according to claim 21, wherein the vector is a virus.

23. (Previously presented) The method according to claim 22, wherein the virus is an adenovirus or an adenovirus-associated virus or retrovirus.

24. (Previously presented) The method according to claim 21, wherein the vector is a plasmid.

25. (Currently amended) ~~The method according to claim 18~~A method of reducing progression of protinuria in a subject suffering from a renal disorder comprising delivering to the kidney of the subject in need thereof a therapeutically effective amount of a gene encoding IL-10, wherein the gene is transfected into a population of cell *in vitro*, wherein the transfected population of cells is administered to the subject.

26. (New) The method according to claim 1, wherein the human cell is infected or transfected with the nucleic acid encoding IL-10 *ex vivo*.

27. (New) The method according to claim 1, wherein the human cell is autologous to said human subject.

28. (New) The method according to claim 18, wherein the human cell is infected or transfected with the nucleic acid encoding IL-10 *ex vivo*.

29. (New) The method according to claim 18, wherein the human cell is autologous to said human subject.

30. (New) The method according to claim 1, wherein the human cell is cultured *in vitro* prior to delivery to said human subject.

31. (New) The method according to claim 18, wherein the human cell is cultured *in vitro* prior to delivering to said human subject.

32. (New) The method according to claim 4, wherein the transfected or infected cell is selected *in vitro* prior to delivery to said human subject.

33. (New) The method according to claim 21, wherein the transfected or infected cell is selected *in vitro* prior to delivering to a human subject.